Cidara Therapeutics Inc (CDTX)

$13.45

+0.1

(+0.75%)

Market is closed - opens 8 PM, 13 Nov 2024

Performance

  • $13.14
    $13.63
    $13.45
    downward going graph

    2.3%

    Downside

    Day's Volatility :3.6%

    Upside

    1.32%

    downward going graph
  • $10.00
    $24.40
    $13.45
    downward going graph

    25.62%

    Downside

    52 Weeks Volatility :59.0%

    Upside

    44.88%

    downward going graph

Returns

PeriodCidara Therapeutics IncIndex (Russel 2000)
3 Months
10.7%
0.0%
6 Months
5.91%
0.0%
1 Year
-13.78%
0.0%
3 Years
-57.7%
-26.7%

Highlights

Market Capitalization
94.1M
Book Value
-$1.81
Earnings Per Share (EPS)
-24.6
PEG Ratio
0.0
Wall Street Target Price
52.4
Profit Margin
-211.35%
Operating Margin TTM
-3675.83%
Return On Assets TTM
-15.66%
Return On Equity TTM
-153.39%
Revenue TTM
53.9M
Revenue Per Share TTM
11.88
Quarterly Revenue Growth YOY
-94.1%
Gross Profit TTM
-11.2M
EBITDA
-30.1M
Diluted Eps TTM
-24.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-25.82
EPS Estimate Next Year
-7.81
EPS Estimate Current Quarter
-4.25
EPS Estimate Next Quarter
-3.75

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Cidara Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 289.59%

Current $13.45
Target $52.40

Technicals Summary

Sell

Neutral

Buy

Cidara Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cidara Therapeutics Inc
Cidara Therapeutics Inc
30.58%
5.91%
-13.78%
-57.7%
-70.63%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-19.05%
-15.96%
3.05%
26.75%
135.72%
Biontech Se
Biontech Se
-11.5%
14.67%
8.57%
-57.55%
473.15%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.07%
79.43%
62.99%
55.18%
196.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
1.07%
13.97%
29.31%
162.23%
136.6%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cidara Therapeutics Inc
Cidara Therapeutics Inc
NA
NA
0.0
-25.82
-1.53
-0.16
NA
-1.81
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.49
1.23
44.94
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.18
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.88
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.35
0.42
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cidara Therapeutics Inc
Cidara Therapeutics Inc
Buy
$94.1M
-70.63%
NA
-211.35%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.0B
135.72%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.1B
473.15%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.1B
196.92%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$133.1B
136.6%
32.84
-4.51%

Insights on Cidara Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 17.58M → 302.0K (in $), with an average decrease of 74.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -89.41M → -15.53M (in $), with an average increase of 475.5% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.0% return, outperforming this stock by 76.8%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 57.4% return, outperforming this stock by 115.6%

Institutional Holdings

  • Monashee Investment Management LLC

    5.24%
  • Bvf Inc

    4.87%
  • Vanguard Group Inc

    2.57%
  • Checkpoint Capital LP

    2.07%
  • Renaissance Technologies Corp

    1.36%
  • Alethea Capital Management, LLC

    1.14%

Company Information

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.

Organization
Cidara Therapeutics Inc
Employees
69
CEO
Dr. Jeffrey L. Stein Ph.D.
Industry
Health Technology

FAQs